丝素蛋白-透明质酸注射喉成形术的独立三级中心疗效分析
结果显示86.2%患者报告嗓音改善,与HA疗效相当,但手术干预率显著高于HA历史队列(6.8% vs 0.6%,p=0.005),严重不良事件未增加。
要点
- silk-HA注射喉成形术在声门闭合不全中安全有效,86.2%患者报告嗓音改善。
- 与HA相比,silk-HA嗓音改善中位评分相当(p=0.776),但手术干预率更高(6.8% vs 0.6%,p=0.005)。
- 多数手术(95.5%)可在诊室完成,严重不良事件未增加。
核心结论
- silk-HA注射喉成形术治疗声门闭合不全安全有效,嗓音结局与HA相当,严重不良事件未增加,但手术修正率较高。
主要发现
- 86.2%患者报告至少轻微嗓音改善,79.3%报告部分至显著改善。
- 20例自身对照中,silk-HA与既往HA的中位改善评分相当(p=0.776)。
- 与同机构历史HA队列(691例,1146次注射)相比,silk-HA手术干预率显著更高(6.8% vs 0.6%,p=0.005)。
- 3例手术干预中,2例为过度填充的选择性修正,1例发生于肺癌进展背景下。
临床怎么用
- silk-HA可作为诊室注射喉成形术的可行选择,但需注意其手术修正率可能高于HA。
局限性
- 回顾性设计、单中心经验、部分患者失访(结局数据仅87.9%),且与历史HA队列比较存在非随机性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of silk protein-hyaluronic acid (silk-HA) injection laryngoplasty for glottic insufficiency at an independent tertiary academic voice center and compare outcomes and complication rates with those of HA injection augmentation. METHODS: We retrospectively reviewed patients undergoing SilkVoice augmentation between June 2022 and August 2025 at a single institution. Outcomes included patient-reported vocal improvement, emergency department visits, hospitalizations, and operative interventions. For patients with prior HA injection, silk-HA outcomes were compared using a within-patient design. RESULTS: Thirty-three patients underwent 44 silk-HA injections (mean age 73.4 years; 51.5% female). Outcome data were available for 29 patients (87.9%). Most procedures (95.5%) were office-based with a mean follow-up of 12.7 months. Overall, 86.2% of patients reported at least minimal vocal improvement and 79.3% reported partial to significant improvement. In a within-patient comparison of 20 patients who received both silk-HA and prior HA, median improvement scores were equivalent (p = 0.776). Compared with a historical HA cohort from the same institution (691 patients, 1146 injections), operative intervention was significantly higher in silk-HA (6.8% vs. 0.6%, p = 0.005); two cases were elective revisions for overaugmentation, and one occurred in the setting of lung cancer progression. CONCLUSION: Silk-HA injection laryngoplasty demonstrates safety and efficacy for glottic insufficiency with voice outcomes comparable to HA and no increase in serious adverse events despite higher operative revision rates. These findings from an independent academic voice center provide external validation supporting silk-HA as a viable office-based augmentation option.
引用
- Wajsberg B, Christ AM, Benyo SE, et al. Silk-Hyaluronic Acid Laryngoplasty Outcomes: An Independent Tertiary Center Experience. Laryngoscope. 2026. PMID: 42248802. doi:10.1002/lary.70665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。